Weight care
Semaglutide
A clinician-guided weight-management program built around your history, not a one-size plan.
$149/month
All-inclusive program price · Illustrative pricing
Product imagery is intended solely for illustrative purposes. Actual medication packaging and pharmacy labeling may differ.
Weight care
Tirzepatide
A clinician-guided weight-management program using tirzepatide, with provider review and one clear monthly price.
$249/month
All-inclusive program price · Illustrative pricing
- Online licensed-provider review
- Secure medical intake after checkout
- Ongoing program support by secure message
- Standard shipping
- Routine follow-up required by the program
May be compounded — not FDA-approved
Available in eligible states, subject to pharmacy and regulatory review.
VitaWellRx® notice. VitaWellRx® is a telehealth platform that connects eligible patients with independent US-licensed providers and licensed pharmacy partners. VitaWellRx® is not a pharmacy and does not itself practice medicine. Prescription products are provided only if clinically appropriate after review by a US-licensed provider.
About this program
The VitaWellRx® Tirzepatide program is a clinician-guided weight-management program. Purchase comes first, the secure medical intake follows, and a licensed clinician determines whether treatment is appropriate.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. The FDA has approved branded tirzepatide products for specific indications. Those branded products are distinct from any compounded tirzepatide formulation, and VitaWellRx® does not describe a compounded formulation as Zepbound or Mounjaro.
This program is generally considered for adults with weight-related health goals who can be managed safely at a distance.
How it may work
Tirzepatide acts on two incretin pathways rather than one. In general educational terms, those pathways are involved in appetite regulation, insulin response, and gastric emptying.
Whether a dual-pathway product suits you better than a single-pathway one is a clinical judgment, not a purchase decision. This page contains no dosing schedule.
Product status
- Any program here may involve a compounded formulation, which is not FDA-approved and is not equivalent to an approved branded drug.
- Availability depends on independent legal, clinical, and pharmacy review.
Eligibility and provider review
Disclose personal or family history of medullary thyroid carcinoma or MEN 2, pancreatitis, gallbladder disease, severe gastrointestinal conditions, diabetes medicines, pregnancy or breastfeeding plans, allergies, and all current medications.
Prescription required. Licensed-provider review required. Not everyone qualifies.
Safety summary
- Gastrointestinal effects are the most commonly described: nausea, vomiting, diarrhoea, constipation, reduced appetite, and abdominal pain.
- Serious risks described for this class include pancreatitis, gallbladder disease, dehydration-related kidney injury, and hypoglycaemia in combination with certain diabetes medicines.
- Seek immediate care for severe or persistent abdominal pain, ongoing vomiting, or allergic symptoms.